Search

Your search keyword '"Ewald, S"' showing total 10 results
Start Over Author "Ewald, S" Publisher wiley
10 results on '"Ewald, S"'

8. The Effect of Fasting on Nnscle Phosphorylase Activity in the Rat

Author

Ewald S. Goranson and Knud Lundbæk

Subjects
Starvation, chemistry.chemical_classification, medicine.medical_specialty, Phosphorylases, Glycogen, Physiology, Muscles, Phosphorylase a, Fasting, Biology, Phosphorylase activity, Enzymes, Rats, Glycogen phosphorylase, chemistry.chemical_compound, Enzyme, Endocrinology, chemistry, Biochemistry, Internal medicine, medicine, Animals, medicine.symptom
Abstract

Summary. The resting niuscle of the fed rat was found to contain a mixture of phosphorylase a and b. The total phosphorylase activity as well as the relative proportion of phosphorylase n was observed to increase during fasting and to decrease on re-feeding. The change in the relative proportion of the two forms of phosphorylase suggests an alteration in the activity of the prostetic-group removing (PR) enzyme. The possible significance of these changes as a mechanism regulating the mobilization of niuscle glycogen during starvation is discussed.

Published
1949
Full Text
View/download PDF

10. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction.

Author

Gittelman M, McMahon CG, Rodríguez-Rivera JA, Beneke M, Ulbrich E, and Ewald S

Subjects
Administration, Oral, Adult, Aged, Double-Blind Method, Humans, Imidazoles adverse effects, Male, Middle Aged, Phosphodiesterase Inhibitors adverse effects, Piperazines adverse effects, Sulfones administration & dosage, Sulfones adverse effects, Tablets, Treatment Outcome, Triazines administration & dosage, Triazines adverse effects, Vardenafil Dihydrochloride, Erectile Dysfunction drug therapy, Imidazoles administration & dosage, Phosphodiesterase Inhibitors administration & dosage, Piperazines administration & dosage
Abstract

Aims: The aim of this study was to investigate the efficacy and safety of 10 mg vardenafil orodispersible tablet (ODT) vs. placebo in a general population of men with erectile dysfunction (ED)., Methods: This was a double-blind, multicentre, randomised, parallel-group, placebo-controlled study conducted at 35 centres in Australia, Canada, Mexico and the United States. Subjects aged > or =18 years, with ED for at least 6 months, were randomised to receive 12 weeks of on-demand treatment with either 10 mg vardenafil ODT or placebo. Each treatment group was stratified such that approximately half of the subjects were aged > or = 65 years. Primary efficacy variables were the erectile function domain of the International Index of Erectile Function (IIEF-EF) and Sexual Encounter Profile questions 2 (SEP2) and 3 (SEP3). Secondary variables included SEP diary questions 1, 4, 5 and 6, the patient version of the Treatment Satisfaction Scale (TSS) and the Global Assessment Question (GAQ)., Results: Of the 473 men enrolled in the study (51.4% aged > or =65 years), 331 were included in the intent-to-treat population (vardenafil ODT, n = 169; placebo, n = 162). Vardenafil ODT therapy was statistically significantly superior to placebo for all primary (i.e. IIEF-EF, SEP2, SEP3) and secondary efficacy variables (p < 0.0001). Treatment-emergent adverse events were mostly mild to moderate in severity, and comparable in both incidence and type with those of the film-coated tablet formulation., Conclusions: Treatment with 10 mg vardenafil ODT, taken on demand, significantly improved erectile function and was effective and well tolerated in a broad population of men with ED.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results